<<Organon believes that it has done enough testing at dose/duration levels similar to those where CX717 evoked the now infamous signals that they see Org24448 does not have the same liability.
And so far the FDA has not raised the possibility of a clinical hold with Org24448.
Does that prove the negative? No more than anything else ever does....>>
Doesn't sound like a "rosy assumption" to me. I wouldn't hold your breath waiting for Stoll to discuss Organon internal studies.
News 
Market Data 
Discover 
AI
